[go: up one dir, main page]

HUP0101545A1 - Peptideket időben elnyújtva kibocsátó gyógyászati készítmények és eljárás az előállításukra - Google Patents

Peptideket időben elnyújtva kibocsátó gyógyászati készítmények és eljárás az előállításukra

Info

Publication number
HUP0101545A1
HUP0101545A1 HU0101545A HUP0101545A HUP0101545A1 HU P0101545 A1 HUP0101545 A1 HU P0101545A1 HU 0101545 A HU0101545 A HU 0101545A HU P0101545 A HUP0101545 A HU P0101545A HU P0101545 A1 HUP0101545 A1 HU P0101545A1
Authority
HU
Hungary
Prior art keywords
preparation
pharmaceutical compositions
release
peptide release
patient
Prior art date
Application number
HU0101545A
Other languages
English (en)
Inventor
Frédéric Bismuth
Marc Pellet
Original Assignee
Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) filed Critical Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)
Publication of HUP0101545A1 publication Critical patent/HUP0101545A1/hu
Publication of HUP0101545A3 publication Critical patent/HUP0101545A3/hu
Publication of HU228903B1 publication Critical patent/HU228903B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány új, peptideket időben elnyújtva kibocsátó gyógyászatikészítményekre és az előállításukra vonatkozó eljárásra vonatkozik. Agélesedő és vízoldékony peptid sót valamint adott esetben alkalmaskötőanyagot tartalmazó szilárd vagy félszilárd gyógyászatikészítményben a peptid só nagy fajlagos felülettel rendelkezik, és abetegbe injektálva a beteg testének anyagaival érintkezve gélesedik,amely gél a peptidet időben elnyújtva, legalább 15 napon át képeskibocsátani. Ó
HU0101545A 1998-03-25 1999-03-22 Pharmaceutical compositions for prolonged peptide release and preparation method HU228903B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9803667A FR2776520B1 (fr) 1998-03-25 1998-03-25 Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
PCT/FR1999/000667 WO1999048517A1 (fr) 1998-03-25 1999-03-22 Compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation

Publications (3)

Publication Number Publication Date
HUP0101545A1 true HUP0101545A1 (hu) 2001-11-28
HUP0101545A3 HUP0101545A3 (en) 2001-12-28
HU228903B1 HU228903B1 (en) 2013-06-28

Family

ID=9524472

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101545A HU228903B1 (en) 1998-03-25 1999-03-22 Pharmaceutical compositions for prolonged peptide release and preparation method

Country Status (19)

Country Link
US (1) US6503534B1 (hu)
EP (1) EP1066049B1 (hu)
JP (1) JP4162381B2 (hu)
AR (1) AR020062A1 (hu)
AT (1) ATE241377T1 (hu)
AU (1) AU756148B2 (hu)
CA (1) CA2324901C (hu)
CZ (1) CZ298941B6 (hu)
DE (1) DE69908326T2 (hu)
DK (1) DK1066049T3 (hu)
ES (1) ES2200507T3 (hu)
FR (1) FR2776520B1 (hu)
HU (1) HU228903B1 (hu)
IL (2) IL138533A0 (hu)
NO (1) NO324621B1 (hu)
PL (1) PL197775B1 (hu)
PT (1) PT1066049E (hu)
RU (1) RU2224538C2 (hu)
WO (1) WO1999048517A1 (hu)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
DK1565160T3 (da) * 2002-09-27 2014-04-28 Terna Zentaris Gmbh Administrationsform til farmaceutisk aktive peptider med vedvarende frigivelse og en fremgangsmåde til fremstilling deraf
RU2255760C2 (ru) * 2003-03-11 2005-07-10 Общество с ограниченной ответственностью фирма "Фермент" Средство, обладающее иммуномодулирующим, противомикробным, антиоксидантным и регенерирующим действием (варианты)
WO2004087102A2 (en) * 2003-03-26 2004-10-14 Teva Pharmaceutical Industries Ltd. A process for preparing a pharmaceutical active ingredient with high specific surface area
PL1684782T3 (pl) 2003-10-03 2016-03-31 Thorn Bioscience Llc Sposób synchronizacji owulacji dla zsynchronizowanego rozmnażania bez wykrywania rui
WO2005058252A2 (en) * 2003-12-16 2005-06-30 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Glp-1 pharmaceutical compositions
US20090023644A1 (en) * 2004-01-13 2009-01-22 Southard Jeffery L Methods of using cgrp for cardiovascular and renal indications
JP2007517913A (ja) * 2004-01-13 2007-07-05 バソジェニックス ファーマシューティカルズ， インコーポレイテッド カルシトニン遺伝子関連ペプチドを投与することによって急性心筋梗塞を処置するための方法およびカルシトニン遺伝子関連ペプチドを含有する組成物
WO2005067890A2 (en) * 2004-01-13 2005-07-28 Vasogenix Pharmaceuticals, Inc. Controlled release cgrp delivery composition for cardiovascular and renal indications
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
GB0428151D0 (en) 2004-12-22 2005-01-26 Novartis Ag Organic compounds
GB0511269D0 (en) * 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
ES2638792T3 (es) * 2005-07-28 2017-10-24 Carbon Sink Inc. Eliminación de dióxido de carbono del aire
GB0517627D0 (en) 2005-08-30 2005-10-05 Tyco Electronics Ltd Uk Bus-bar and connector
ES2779992T3 (es) 2005-12-20 2020-08-21 Univ Duke Métodos y composiciones para suministrar agentes activos con propiedades farmacológicas potenciadas
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20070219811A1 (en) * 2006-03-16 2007-09-20 Kim John S Method for using an internet-based CRM application to create an on-line leads marketplace
AU2007339280B2 (en) * 2006-12-21 2013-12-05 Stryker Corporation Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents
JP2010523501A (ja) * 2007-04-04 2010-07-15 セラテクノロジーズ インコーポレイティド Ｇｈｒｈ分子の医薬製剤
TWI539959B (zh) 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
CA2726894A1 (en) 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
EP2421545B1 (en) 2009-04-23 2017-12-06 JBS United Animal Health II LLC Method and composition for synchronizing time of insemination
AU2010243273B2 (en) 2009-05-01 2016-06-16 Ferring B.V. Composition for the treatment of prostate cancer
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
CA2804755C (en) 2009-08-14 2018-06-05 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
JP6029472B2 (ja) * 2010-01-13 2016-11-24 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． ソマトスタチン類似体（アナログ）の持続的放出のための医薬組成物の製造方法
LT2632934T (lt) 2010-10-27 2017-01-10 Ferring B.V. Degarelikso ir jo tarpinių darinių gamybos būdas
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
EP2717902B1 (en) 2011-06-06 2018-01-24 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
DE102011114864A1 (de) 2011-10-05 2013-04-11 Acino Ag Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
PL4512389T1 (pl) 2012-06-01 2025-09-01 Ferring B.V. Produkt leczniczy degareliksu
JP2016508030A (ja) 2012-11-28 2016-03-17 ジェイビーエス ユナイテッド アニマル ヘルス セカンド エルエルシー 未経産ブタにおける授精の時期を同期化するための方法および組成物
EP2823808A1 (en) 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
EP2910255A1 (en) * 2014-02-19 2015-08-26 MedSkin Solutions Dr. Suwelack AG Methods for the production of biopolymers with defined average molecular weight
TW201625218A (zh) * 2014-04-18 2016-07-16 Ｊｂｓ聯合動物保健有限責任公司 製造含ｇｎｒｈ凝膠之方法
WO2015172046A1 (en) 2014-05-08 2015-11-12 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
AU2016219513B2 (en) 2015-02-09 2021-09-30 Immunoforge Co., Ltd. Methods and compositions for treating muscle disease and disorders
WO2020170185A1 (en) * 2019-02-21 2020-08-27 Dr. Reddy’S Laboratories Limited Substantially pure lanreotide or its salt & process thereof
GR1009814B (el) * 2019-07-29 2020-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει ενα πεπτιδιο αναλογο σωματοστατινης
CN110577567A (zh) * 2019-09-03 2019-12-17 杭州诺泰澳赛诺医药技术开发有限公司 一种制备高比表面积活性多肽或蛋白的方法
WO2023092148A1 (en) * 2021-11-22 2023-05-25 SpecGx LLC Injectable sustained release pharmaceutical composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69005800T2 (de) * 1989-05-01 1994-05-19 Alkermes Inc Verfahren zur herstellung von kleinen partikeln von biologisch aktiven molekülen.
JP3100005B2 (ja) * 1992-07-28 2000-10-16 雪印乳業株式会社 ヒト免疫不全ウィルス感染・増殖抑制剤
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions

Also Published As

Publication number Publication date
DE69908326D1 (de) 2003-07-03
RU2224538C2 (ru) 2004-02-27
HUP0101545A3 (en) 2001-12-28
EP1066049A1 (fr) 2001-01-10
AU756148B2 (en) 2003-01-02
US6503534B1 (en) 2003-01-07
DE69908326T2 (de) 2004-03-25
EP1066049B1 (fr) 2003-05-28
NO324621B1 (no) 2007-11-26
NO20004741D0 (no) 2000-09-22
CA2324901A1 (fr) 1999-09-30
NO20004741L (no) 2000-11-22
AU2938499A (en) 1999-10-18
ES2200507T3 (es) 2004-03-01
FR2776520A1 (fr) 1999-10-01
JP4162381B2 (ja) 2008-10-08
PL343005A1 (en) 2001-07-30
WO1999048517A1 (fr) 1999-09-30
AR020062A1 (es) 2002-04-10
PL197775B1 (pl) 2008-04-30
CA2324901C (fr) 2012-01-24
CZ20003432A3 (cs) 2001-02-14
IL138533A (en) 2006-12-31
FR2776520B1 (fr) 2000-05-05
ATE241377T1 (de) 2003-06-15
DK1066049T3 (da) 2003-09-29
IL138533A0 (en) 2001-10-31
HU228903B1 (en) 2013-06-28
JP2002507578A (ja) 2002-03-12
CZ298941B6 (cs) 2008-03-19
PT1066049E (pt) 2003-10-31

Similar Documents

Publication Publication Date Title
HUP0101545A1 (hu) Peptideket időben elnyújtva kibocsátó gyógyászati készítmények és eljárás az előállításukra
DE69531741D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
EG20401A (en) Process for preparing of veterinary composition for the treatment of gastric acid related deseases in animals
AU6819294A (en) Oral drug delivery compositions and methods
EP0300189A3 (en) New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
ID28003A (id) Turunan-turunan adamantana
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
HUP0000299A1 (hu) Késleltetett hatóanyag-leadású gyógyszerkészítmények
EP0887075A3 (en) Adhesive mixture for transdermal delivery of highly plasticizing drugs
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
PT848720E (pt) Antagonistas da actividade oncogenica da proteina mdm2 e sua utilizacao no tratamento de cancros
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
GR3024529T3 (en) Pellets containing peptide drugs, their manufacture and use.
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
ITRM910730A0 (it) Composizioni farmaceutiche, per uso topico, contenenti "scavengers" diradicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali
ES8703742A1 (es) Procedimiento para preparar un agente acuoso esteril de ac- cion retardada y prolongada,de un peptido o de una proteina
NZ230356A (en) 2',3'-dideoxy-5-ethynyl-3'-fluorouridine: preparatory processes and pharmaceutical compositions
AU3739500A (en) Protease resistant flint analogs
CA2290739A1 (en) New bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy
IL112435A0 (en) A pharmaceutical composition containing an acid active substance and processes for the preparation thereof
CA2205564A1 (en) Pharmaceutical compositions comprising nitric oxide-releasing biopolymers
BG101846A (en) HUMAN DNase I VARIANTS
DK0927031T3 (da) Farmaceutisk sammensætning indeholdende nimesulid til oral admnistration
EP0341661A3 (en) Peptide-drug compositions containing alpha-aminoboronic acid derivatives
CA2247998A1 (en) Fragments of cr1 and their use

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: IPSEN PHARMA S.A.S., FR

Free format text: FORMER OWNER(S): SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.), FR